Expanded Access Study of Iodine-131 Anti-B1 Antibody
Not Applicable
- Conditions
- Non-Hodgkin's Lymphoma
- Registration Number
- NCT00022958
- Lead Sponsor
- Corixa Corporation
- Brief Summary
The primary objective of this study is to make Iodine-131 Anti-B1 Antibody more broadly available to patients. Secondary endpoints of the study will be to obtain additional information on the efficacy and safety of Iodine-131 Anti-B1 Antibody.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Central Recruiting Information
🇺🇸South San Francisco, California, United States